ABCL AbCellera Biologics Inc.
$11.12
AbCellera Biologics Inc. (ABCL) Earnings News
Earnings press releases, previews and reviews for AbCellera Biologics Inc. (ABCL), newest first. Our most recent is review: AbCellera Tops Estimates, but ABCL635's Breakout Phase 2 Data and a $900 Million War Chest Are the Real Story.
Monday
November 9, 2026
8:48 PM ET
AbCellera Tops Estimates, but ABCL635's Breakout Phase 2 Data and a $900 Million War Chest Are the Real Story
Earnings Whispers · Review
Monday
November 9, 2026
4:05 PM ET
AbCellera Reports Q3 2026 Business Results
Monday
November 2, 2026
4:25 PM ET
AbCellera Heads Into Results With Stock Doubled and ABCL635 Phase 2 Data Taking Center Stage
Earnings Whispers · Preview
Thursday
October 1, 2026
4:05 PM ET
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Wednesday
August 5, 2026
4:05 PM ET
AbCellera Reports Q2 2026 Business Results
Thursday
July 23, 2026
9:05 AM ET
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
Wednesday
July 15, 2026
8:45 AM ET
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
Tuesday
July 7, 2026
4:05 PM ET
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026